(See published press release at link.)
The use of stem cells, allografts, autografts and other cell and tissue types for the treatment of disorders and conditions has succeeded from a clinical standpoint for their ability to be rapidly accepted by the human body and their specificity to the disease state. This has been most clearly the case in orthopedics and skin/integumentary treatments, where the practice of bone, ligament, cartilage, skin and other tissue repair practices have driven the creation of a current $6 billion market. However, acute care applications — in cardiology, cancer, neurology and other clinical areas have become established and will help drive the aggregate global cell/tissue market to nearly $32 billion in less than ten years, according to a new MedMarket Diligence report. (See http://mediligence.com/
"Where cell therapies and tissue engineering have historically demonstrated their greatest success have been in the treatment of chronic conditions and disorders in which the clinical need is a substantive replacement of tissue, as in filling bone defects or voids, skin graft replacements and similar, a wave of new cell and tissue technologies have been approved, or on the horizon, to provide more complicated physiological and functional solutions to disease states. Revascularization in ischemic heart disease, cell therapies for diabetes, Parkinson's, Alzheimers, spinal cord repair and others with significant clinical need and market demand are entering the market and creating sustainable revenue streams for a growing list of innovative manufacturers,"
According to Driscoll, the growth of the global cell therapy and tissue engineering market is at least double digit on an annual basis for nearly all clinical segments, spanning orthopedics, skin/integumentary, cardiology, neurology, organ repair/replacement, dental/oral surgery, and, especially, cancer.
In terms of clinical specialties, the segment expected to experience the most rapid growth is organ transplantation and related technologies. Over the 2009–2018 period, this segment is expected to grow by roughly 46%. This unusually explosive growth is expected due to: (1) the large demand for effective therapies for chronic diseases as those involving the pancreas (diabetes), liver and heart; and (2) development of regenerative technologies related to therapies for these diseases is among the most advanced among all gene and cell therapy-based developments.
The segment expected to grow the second most rapidly from 2009 to 2018 comprises therapies for dental decay and disease. The growth rate expected here is roughly 21%. Several technologies in this segment, such as bone and tissue grafts, are already being marketed rather but rather than hitting a plateau, growth in this segment expected to be sustained by an aging population that will result in an increase in the numbers of people who can benefit from these therapies.
MedMarket Diligence predict that regenerative medicine with applications in cardiology and vascular medicine will rank among the three fastest growing segments found in the market. This growth, to equal roughly 20% from 2009 to 2018, is expected to result from commercialization of several innovative therapies that are expected to reach regulatory approval status.
The MedMarket Diligence report, "Tissue Engineering, Cell Therapy and Transplantation:
The MedMarket Diligence Report #S520 on Cell Therapy and Tissue Engineering is described, with detailed table of contents and list of exhibits, at http://mediligence.com/
# # #
MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.